First high potency oral drug facility opened by Wuxi STA

China-based Contract Research Development and Manufacturing Organization (CRDMO) WuXi STA has opened its first high potency (HP) oral drug product manufacturing facility at its Wuxi city campus.

The fast-growing company said this his new facility marks a milestone for WuXi STA, further extending its drug product capacity and capabilities to meet the growing demand for HP drug candidate development and manufacturing services.

With this new facility, WuXi STA is well positioned to provide an integrated R&D and manufacturing network for high potency active pharmaceutical ingredients (HPAPI) and drug product from preclinical to commercial manufacturing. Specifically, this facility will complement the services and offerings of WuXi STA's existing HPAPI facilities in Changzhou and Shanghai Jinshan, which are near Wuxi city.